Expert Interview
A Review of FTX-6058 in treating sickle cell disease following the update from EHA
Ticker(s): FULCInstitution: Rutgers Medical School
- Clinical Section Chief, Pediatric Hematology/Oncology and Director, Comprehensive Sickle Cell Center at Rutgers Cancer Institute of New Jersey; Vice Chair, IRB at Rutgers Biomedical and Health Sciences; and Vice Chair, NCI Pediatric Central IRB.
- Currently manages 450 patients with sickle cell disease and sees 20/year with cisplatin induced hearing loss.
- Research focuses on Hodgkin Disease, Pediatric oncology/ hematology, and Sickle cell disease.
Roughly how many patients with sickle cell disease do you currently manage?
Added By: c_adminWhat were your thoughts on the initial data from the ongoing Phase 1b trial of FTX-6058?
Added By: c_adminOn a scale from 1-10, 10 being extremely excited, where would you rate your level of excitement for FTX-6058?
Added By: c_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
